Published on 06/12/2025
Regulatory differences between biosimilarity and interchangeability in the USA
Context
The regulation of biosimilars has evolved significantly in recent years, particularly with the establishment of legal and scientific frameworks designed to oversee their development, approval, and market access. In the United States, the Biologics Control Act and the Biologics Price Competition and Innovation Act (BPCIA) serve as critical statutes governing this area. Key distinctions arise between biosimilarity—where a biologic is demonstrated to be highly similar to an already licensed reference product—and interchangeability, where the biosimilar is deemed suitable for substitution for the reference product without the intervention of the prescriber. This article covers the regulatory nuances of these concepts, particularly focusing on the requirements set forth by the US Food and Drug Administration (FDA) regarding interchangeability designation and the necessary switching studies involved.
Legal/Regulatory Basis
Framework for Biosimilars in the USA
The FDA operates under several regulations relevant to biosimilars and interchangeability. The foundational regulatory framework established under the Biologics Control Act and the BPCIA (sections 351(k) of the Public Health Service Act) differentiates how biosimilars are approved and subsequently regulated. A biosimilar must meet rigorous standards
Key Definitions
- Biosimilar: A biological product that is highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, effectiveness, or purity.
- Interchangeable Biosimilar: A biosimilar that may be substituted for the reference product without the intervention of the healthcare prescriber. The approved product must demonstrate that it is not only biosimilar but can also be expected to produce the same clinical result in any patient.
Documentation
Requirements for Biosimilarity and Interchangeability
The documentation required for demonstrating biosimilarity and interchangeability varies significantly. For a biosimilar application under BPCIA, sponsors must utilize the 351(k) application process. The specific focus for interchangeability requires extensive additional data.
Data Components
- Comparative Data: Rigorous comparative studies that demonstrate that the biosimilar is highly similar to the reference product.
- Switching Studies: Required studies to demonstrate the safety and efficacy of switching between the biosimilar and reference product. Clinical studies must show that switching does not negatively impact immunogenicity, safety, or efficacy.
Review/Approval Flow
Application Submission
The submission of a biosimilar application is carried out using the FDA’s Electronic Submissions Gateway. A successful application must include a comprehensive data package that aligns with FDA guidelines relating to biosimilars and interchangeability.
Fast-Track and Priority Review
Depending on the context, biosimilar applications may be eligible for expedited review processes, including fast-track or priority review designation. Applications leveraging these statuses must provide convincing arguments that highlight the substantial clinical advantages of the product over existing therapies.
Common Deficiencies
Typical Agency Questions and Responses
Equipped with an understanding of the regulatory landscape, sponsors must be prepared for typical deficiencies and questions raised by the FDA during the review of biosimilar applications that seek interchangeability designation.
Common Deficiencies
- Insufficient Evidence of Interchangeability: The FDA may raise concerns if data on switching studies are inadequate or fail to demonstrate that switching from the reference to the biosimilar does not affect the clinical outcome.
- Immunogenicity Data Gaps: Sponsors must be vigilant in providing robust immunogenicity data. Design flaws or inadequate statistical models can lead to potential deficiencies.
- Equivalence of Safety and Efficacy: The FDA expects clear data indicating that the safety and efficacy between biosimilars and reference products are equivalent across populations.
RA-Specific Decision Points
Filing as a Variation vs. New Application
One critical decision point is determining when to file as a variation to an existing application versus submitting a new application. Generally, if there are minor changes substantiated by bridging data, a variation should be considered. However, significant changes, especially those that impact the product’s pharmacokinetics or risk profile, may necessitate a new application submission.
Justifying Bridging Data
When attempting to justify bridging data, regulatory professionals should emphasize the scientific rationale behind any proposed changes, including the relevance of manufacturing processes, changes in formulation, or new indications. The objective is to alleviate apprehensions by validating that the clinical and analytical data provided support continued assurance following the modification.
Conclusion
Understanding the differences between biosimilarity and interchangeability within the US regulatory framework is critical for regulatory affairs professionals involved in the development of biosimilars. By adhering to the defined processes and meeting the agency’s expectations, along with a rigorous scientific approach to switching studies, sponsors can increase the likelihood of a successful application approval. Continued engagement with the FDA’s evolving guidance in this sector and meticulous documentation will remain vital components in the biosimilar development journey.